On Apr. 24, 2019, Bellamy announced that a new Bellamy’s b325 mg ferrous sulfate side effectsranded infant formula product line was to be produced at the ViPlus Dairy (ViPlus) facility. The product line has already been granted registration approval by China SAMR and it was awaiting finairon bisglycinate or ferrous fumaratel certification [1]. Stimulated by this inspiring news, 256 mg ferrous sulfateBellamy’s share price jumped to 11.29 Australian dollars per share that day, represferrous fumarate gi side effectsenting a 17.36% increase. However, after our investigations we have discovered that the product is not a newferrous gluconate for pregnancy formula and just involves a slight tweak in the registered information (basically just a change of name) of a previously registered Viplus product.
Bellamy to Exploit China Infant Formula General Trade Channels through Registered Proxy
